Related Experiment Video
Updated: Jul 11, 2026
06:52
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
Published on: July 22, 2020
6.6K
Transcriptomic screening to identify hub genes and drug signatures for PCOS based on RNA-Seq data in granulosa cells.
M Zanjirband1, M Baharlooie2, Z Safaeinejad1
1Department of Animal Biotechnology, Reproductive Biomedicine Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran.
Computers in Biology and Medicine
|February 4, 2023
Summary
This study identifies new drug targets for Polycystic Ovary Syndrome (PCOS) by analyzing granulosa cell gene expression. Promising FDA-approved and investigational drugs like melatonin show potential for PCOS treatment.
Area of Science:
- Endocrinology
- Genomics
- Pharmacology
Background:
- Polycystic Ovary Syndrome (PCOS) is a leading cause of female infertility.
- Granulosa cells are crucial for follicle development and hormone synthesis in PCOS.
- Current FDA-approved treatments for PCOS are limited.
Purpose of the Study:
- To identify novel therapeutic targets for PCOS.
- Focus on granulosa cell transcriptome analysis.
- Utilize a drug repositioning approach.
Main Methods:
- Screening and reanalysis of PCOS granulosa cell datasets (microarray, RNA-Seq).
- KEGG pathway enrichment and protein-protein interaction network analysis.
- Drug signature screening and poly-pharmacology survey.
Main Results:
- Identified 545 differentially expressed genes and 18 hub genes in granulosa cells.
- Key enriched pathways include xenobiotic metabolism and steroidogenesis.
- Identified potential drug candidates like melatonin, resveratrol, and raloxifene, with 21 targets overlapping differentially expressed genes.
Conclusions:
- The study presents approved and investigational drug signatures for PCOS based on granulosa cell gene expression.
- Findings offer potential avenues for improved PCOS management.
- Data supports further research into drug repositioning for PCOS therapeutics.
